Arikayce savings card: as little as $0 a month with commercial insurance

How to pay the least

Ask for the cash price

Arikayce

We didn’t find one.

Ask your pharmacy for Arikayce’s cash price, and one or two other pharmacies too.
Arikayce’s savings card works only with insurance from a job or one you bought.

Compare every option

Brand nameArikayce

Authorized genericamikacin

Regular genericamikacin

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Arikayce?

The original

–

Brand nameThe maker’s card

ARIKAYCE Copay Savings Program (inLighten)

Savings card from Insmed

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a month

Or call 1-833-544-4800. See the offer on arikayce.com

In the maker’s words

“Patients who are eligible may pay as little as a $0 copay every month.”

From the maker’s offer on arikayce.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Arikayce itself, from the same company, sold without the brand name, and usually for less. For now Arikayce is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Hard-to-treat MAC lung disease (Mycobacterium avium complex)

What the FDA label says

LIMITED POPULATION: ARIKAYCE is an aminoglycoside antibacterial indicated in adults who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients.

This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established.

Limitation of Use:

ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.

Source: the FDA label for Arikayce (Insmed Incorporated), August 4, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/arikayce/